CRANFORD, N.J., Jan. 2, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and ...

Catheter lock therapy (CLT) may be used in addition to systemic therapy with the aim of reducing treatment failure by targeting biofilm bacteria. A small dose of antimicrobial agent is instilled to ...

Trial achieves statistically significant primary endpoint (p=0.0006) Secondary endpoint demonstrates statistically significant overall success of Mino-Lok therapy with a greater percentage of patients ...

CRANFORD, N.J., April 29, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company dedicated to the development and ...

A study published in Clinical Infectious Diseases examined the cost-effectiveness of antimicrobial locks for the prevention of central line-associated bloodstream infections. Antibiotic lock therapy ...

CRANFORD, N.J., Aug. 10, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical ...

The Mino-Lok ® Phase 3 pivotal superiority trial (NCT02901717) is a multi-center, randomized, open-label, blinded study to determine the efficacy and safety of Mino-Lok ® (MLT), a novel antibiotic ...

In order to minimize the risk of hemodialysis catheter-related bacteremia (CRB), the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines advocate use of tunneled ...

Please provide your email address to receive an email when new articles are posted on . “Our goal in this study was to evaluate whether an antibiotic timeout by frontline clinicians after 3 to 5 days ...

CRANFORD, N.J., April 29, 2021 /PRNewswire/ — Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (Nasdaq: CTXR), a specialty pharmaceutical company dedicated to the development and ...

Blood cultures should be collected from at least 2 sites before initiation of antibiotics (ideally from all lumens of a multilumen CVC). Peripheral blood culture should be collected when possible.